Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | METAP1 | P53582 | 1/20 | 0.40 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.39 |
| ▸ | ADH1B | P00325 | 1/20 | 0.39 |
| ▸ | ADH1C | P00326 | 1/20 | 0.39 |
| ▸ | ADH1A | P07327 | 1/20 | 0.39 |
| ▸ | ADH4 | P08319 | 1/20 | 0.39 |
| ▸ | ADH7 | P40394 | 1/20 | 0.39 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.36 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.36 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.36 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.36 |
| ▸ | DAO | P14920 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL60593 | 1.00 | — | — | |
| SCHEMBL3027711 | 1.00 | CYP1A2 (0.48) | CYP1A2SIGMAR1HPGDMETAP1EPHX1 | |
| SCHEMBL8176343 | 1.00 | CYP1A2 (0.48) | CYP1A2SIGMAR1HPGDMETAP1EPHX1 | |
| SCHEMBL866084 | 1.00 | CYP1A2 (0.48) | CYP1A2SIGMAR1HPGDMETAP1EPHX1 | |
| SCHEMBL867086 | 1.00 | CYP1A2 (0.48) | CYP1A2SIGMAR1HPGDMETAP1EPHX1 | |
| SCHEMBL866633 | 1.00 | CYP1A2 (0.48) | CYP1A2SIGMAR1HPGDMETAP1EPHX1 | |
| SCHEMBL21831394 | 1.00 | CYP1A2 (0.48) | CYP1A2SIGMAR1HPGDMETAP1EPHX1 | |
| SCHEMBL21114318 | 1.00 | CYP1A2 (0.48) | CYP1A2SIGMAR1HPGDMETAP1EPHX1 | |
| SCHEMBL21831579 | 1.00 | CYP1A2 (0.48) | CYP1A2SIGMAR1HPGDMETAP1EPHX1 | |
| SCHEMBL22434 | 0.97 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 708 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116903480-A | Method for preparing beta-enaminone based on sulfoxide and aldoxime and beta-enaminone | 盐城师范学院 | 2023-10-20 | — | — | CN | claimed |
| CN-111233786-B | Benzene sulfonamide compound containing five-membered heterocycle and preparation method and application thereof | 中国人民解放军军事科学院军事医学研究院 | 2021-11-26 | — | — | CN | claimed |
| CN-111233786-A | Benzene sulfonamide compound containing five-membered heterocycle and preparation method and application thereof | 中国人民解放军军事科学院军事医学研究院 | 2020-06-05 | — | — | CN | claimed |
| CN-110143886-A | The method of the preparation such as beta-aromatic alkamine drug of tulobuterol, Clorprenaline, isoproterenol and Sotalol | 北京化工大学 | 2019-08-20 | — | — | CN | claimed |
| CN-110117220-A | A kind of preparation method of naphthene amino phenol intermediate | 中国科学院长春应用化学研究所 | 2019-08-13 | — | — | CN | claimed |
| US-20100298285-A1 | Biclycloheteroaryl Compounds as P2x7 Modulators and Uses Thereof | RENOVIS, INC. | 2010-11-25 | — | — | US | claimed |
| US-20090105482-A1 | Urea Glucokinase Activators | NOVO NORDISK A/S (DK) | 2009-04-23 | — | — | US | claimed |
| WO-2007109182-A2 | BICYCLOHETEROARYL COMPOUNDS AS P2X7 MODULATORS AND USES THEREOF | RENOVIS, INC. (US) | 2007-09-27 | — | — | WO | claimed |
| EP-1528059-A2 | Substituted isoxazoles for the treatment of inflammation | G.D. Searle LLC (US) | 2005-05-04 | — | — | EP | claimed |
| EP-1223167-A2 | Substituted isoxazoles for the treatment of inflammation | G.D. Searle & Co. (US) | 2002-07-17 | — | — | EP | claimed |
| US-5985902-A | TREATING INFLAMMATION AND INFLAMMATION-ASSOCIATED DISORDERS, SUCH AS ARTHRITIS | G.D. SEARLE & CO. (US) | 1999-11-16 | — | — | US | claimed |
| US-5859257-A | ANTIINFLAMMATORY, ANTIARTHRITIC AGENTS | G. D. SEARLE & CO. (US) | 1999-01-12 | — | — | US | claimed |
| EP-0809636-A1 | SUBSTITUTED ISOXAZOLES FOR THE TREATMENT OF INFLAMMATION | G.D. SEARLE & CO. (US) | 1997-12-03 | — | — | EP | claimed |
| US-5633272-A | Substituted isoxazoles for the treatment of inflammation | PHARMACIA & UPJOHN COMPANY LLC | 1997-05-27 | — | — | US | claimed |
| WO-1996025405-A1 | SUBSTITUTED ISOXAZOLES FOR THE TREATMENT OF INFLAMMATION | G.D. SEARLE & CO. (US) | 1996-08-22 | — | — | WO | claimed |
| EP-3597670-B1 | WATER-SOLUBLE COMPOSITION, PRODUCTION METHOD FOR CURED PRODUCT THEREOF, AND CURED PRODUCT THEREOF, AND ACYL PHOSPHINATE | ADEKA CORP (JP) | 2024-07-10 | — | — | EP | disclosed |
| CN-118206525-A | Aromatic ring [ d ] thiazepine ketone compound and preparation method thereof | 北京化工大学 | 2024-06-18 | — | — | CN | disclosed |
| EP-0010067-A2 | Process for influencing plant growth | CIBA-GEIGY AG (CH) | 1980-04-16 | — | — | EP | disclosed |
| EP-0002039-A1 | Phosphonous acid derivatives, processes for their preparation and their use in combating microorganisms | CIBA-GEIGY AG (CH) | 1979-05-30 | — | — | EP | disclosed |
| US-3971825-A | (5,6) (10,11) BIS-METHYLENE, BRONCHODILATORS | SANKYO COMPANY LIMITED (JA) | 1976-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298285-A1 | Biclycloheteroaryl Compounds as P2x7 Modulators and Uses Thereof | P2RX7, P2RX3, P2RX1 | CYP1A2 1650/4885SIGMAR1 701/4885HPGD 430/4885 |
| US-20090105482-A1 | Urea Glucokinase Activators | GCK, GCKR, HK2 | CYP1A2 1207/4885SIGMAR1 4399/4885HPGD 1380/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.